Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun 13;32(7):427.
doi: 10.1007/s00520-024-08627-8.

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life

David Balayssac  1 , Nicolas Kerckhove  2 , Marie Selvy  2 , Bruno Pereira  3 , Coralie Gonneau  4 , Caroline Pétorin  5 , Agnès Vimal-Baguet  5 , Sergey Melnikov  6 , Sharif Kullab  7 , Mohamed Hebbar  8 , Olivier Bouché  9 , Florian Slimano  10 , Vincent Bourgeois  11 , Valérie Lebrun-Ly  12 , Frédéric Thuillier  12 , Thibault Mazard  13 , David Tavan  14 , Kheir-Eddine Benmammar  15 , Brigitte Monange  15 , Mohamed Ramdani  16 , Denis Péré-Vergé  17 , Floriane Huet-Penz  18 , Ahmed Bedjaoui  19 , Florent Genty  20 , Cécile Leyronnas  21 , Denis Pezet  22 , Vincent Martin  23
Affiliations
Free article
Multicenter Study

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life

David Balayssac et al. Support Care Cancer. .
Free article

Abstract

Purpose: Sensory chemotherapy-induced peripheral neuropathy (CIPN) is well-recognized, but motor CIPN remains understudied. This secondary analysis focused on the long-term severity and impact of motor disorders, their relation to sensory CIPN, neuropathic pain, psychological distress, and health-related quality of life (HRQoL) after oxaliplatin-based chemotherapy in colorectal cancer (CRC) survivors.

Methods: Data from a multicenter, cross-sectional study were re-analyzed to explore motor CIPN among CRC survivors up to 5 years post-chemotherapy, with no longitudinal follow-up. Questionnaires assessed sensory and motor CIPN (QLQ-CIPN20), neuropathic pain (DN4), anxiety and depression (HADS), and HRQoL (QLQ-C30).

Results: Among 405 CRC survivors, 31.1% had sensory CIPN as previously described. When categorizing the 405 CRC survivors based on the years since their last oxaliplatin-based chemotherapy, the motor scores derived from the QLQ-CIPN20 showed no significant difference between years (p = 0.08). Motor CIPN scores correlated with female gender, higher oxaliplatin dose intensity, sensory CIPN, and neuropathic pain. Motor CIPN also linked to decreased HRQoL and increased psychological distress.

Conclusion: The study underscores the detrimental impact of motor disorders on CRC survivors post-oxaliplatin-based chemotherapy. Oncologists should prioritize assessing and managing motor manifestations alongside sensory symptoms to enhance post-cancer quality of life.

Trial registration: NCT02970526 (2016-11-22). https://classic.

Clinicaltrials: gov/ct2/show/NCT02970526?term=NCT02970526&draw=2&rank=1 .

Keywords: Cancer survivors; Chemotherapy-induced peripheral neuropathy; Colorectal cancer; Motor disorders; Oxaliplatin.

PubMed Disclaimer

References

    1. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351. https://doi.org/10.1056/NEJMoa032709 - DOI - PubMed
    1. Kerckhove N, Collin A, Condé S et al (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 8:86. https://doi.org/10.3389/fphar.2017.00086 - DOI - PubMed - PMC
    1. Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol 38:3325–3348. https://doi.org/10.1200/JCO.20.01399 - DOI
    1. Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 31:1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003 - DOI
    1. Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol Off J Am Soc Clin Oncol 27:5727–5733. https://doi.org/10.1200/JCO.2009.23.4344 - DOI

Publication types

Associated data